

1 CLAIMS

2 What is claimed is:

3 Claim 1. An isolated monoclonal antibody or antigen binding fragments  
4 thereof encoded by the clone deposited with the ATCC as Accession Number PTA-5305.

5  
6 Claim 2. The isolated antibody or antigen binding fragments of claim 1,  
7 wherein said isolated antibody or antigen binding fragments thereof is humanized.

8  
9 Claim 3. The isolated antibody or antigen binding fragments of claim 1  
10 conjugated with a member selected from the group consisting of cytotoxic moieties,  
11 enzymes, radioactive compounds, and hematogenous cells.

12  
13 Claim 4. The isolated antibody or antigen binding fragments of claim 1,  
14 wherein said isolated antibody or antigen binding fragments thereof is a chimerized  
15 antibody.

16  
17 Claim 5. The isolated antibody or antigen binding fragments of claim 1,  
18 wherein said isolated antibody or antigen binding fragments thereof is a murine antibody.

1           Claim 6.       The isolated clone deposited with the ATCC as Accession Number  
2   PTA-5305.

3

4           Claim 7.       A binding assay to determine presence of cancerous cells in a tissue  
5   sample selected from a human tumor comprising:

6           providing a tissue sample from said human tumor ;

7           providing an isolated monoclonal antibody or antigen binding fragment thereof  
8   encoded by the clone deposited with the ATCC as Accession Number PTA-5305;

9           contacting said isolated monoclonal antibody or antigen binding fragment thereof  
10   with said tissue sample; and

11          determining binding of said isolated monoclonal antibody or antigen binding  
12   fragment thereof with said tissue sample;

13          whereby the presence of said cancerous cells in said tissue sample is indicated.

14

15          Claim 8.       The binding assay of claim 7 wherein the human tumor tissue  
16   sample is obtained from a tumor originating in a tissue selected from the group consisting  
17   of colon, ovarian, lung, prostate, pancreatic and breast tissue.

18

19          Claim 9.       A process of isolating or screening for cancerous cells in a tissue  
20   sample selected from a human tumor comprising:

1 providing a tissue sample from a said human tumor ;  
2 providing an isolated monoclonal antibody or antigen binding fragment thereof  
3 encoded by the clone deposited with the ATCC as Accession Number PTA-5305;  
4 contacting said isolated monoclonal antibody or antigen binding fragment thereof  
5 with said tissue sample; and  
6 determining binding of said isolated monoclonal antibody or antigen binding  
7 fragment thereof with said tissue sample;  
8 whereby said cancerous cells are isolated by said binding and their presence in said  
9 tissue sample is confirmed.

10

11 Claim 10. The process of claim 9 wherein the human tumor tissue sample is  
12 obtained from a tumor originating in a tissue selected from the group consisting of colon,  
13 ovarian, lung, and breast tissue.

14

15 Claim 11. An isolated monoclonal antibody or antigen binding fragments  
16 thereof encoded by the clone deposited with the ATCC as Accession Number PTA-5306.

17

18 Claim 12. The isolated antibody or antigen binding fragments of claim 11,  
19 wherein said isolated antibody or antigen binding fragments thereof is humanized.

20

1           Claim 13.     The isolated antibody or antigen binding fragments of claim 11  
2 conjugated with a member selected from the group consisting of cytotoxic moieties,  
3 enzymes, radioactive compounds, and hematogenous cells.

4

5           Claim 14.     The isolated antibody or antigen binding fragments of claim 11,  
6 wherein said isolated antibody or antigen binding fragments thereof is a chimerized  
7 antibody.

8

9           Claim 15.     The isolated antibody or antigen binding fragments of claim 11,  
10 wherein said isolated antibody or antigen binding fragments thereof is a murine antibody.

11

12           Claim 16.     The isolated clone deposited with the ATCC as Accession Number  
13 PTA-5306.

14

15           Claim 17.     A binding assay to determine presence of cancerous cells in a tissue  
16 sample selected from a human tumor comprising:

17           providing a tissue sample from said human tumor ;

18           providing an isolated monoclonal antibody or antigen binding fragment thereof  
19 encoded by the clone deposited with the ATCC as Accession Number PTA-5306;

1           contacting said isolated monoclonal antibody or antigen binding fragment thereof  
2 with said tissue sample; and  
3           determining binding of said isolated monoclonal antibody or antigen binding  
4 fragment thereof with said tissue sample;  
5           whereby the presence of said cancerous cells in said tissue sample is indicated.  
6

7           Claim 18.     The binding assay of claim 17 wherein the human tumor tissue  
8 sample is obtained from a tumor originating in a tissue selected from the group consisting  
9 of colon, ovarian, lung, prostate, pancreatic and breast tissue.  
10

11          Claim 19.     A process of isolating or screening for cancerous cells in a tissue  
12 sample selected from a human tumor comprising:  
13           providing a tissue sample from a said human tumor ;  
14           providing an isolated monoclonal antibody or antigen binding fragment thereof  
15 encoded by the clone deposited with the ATCC as Accession Number PTA-5306;  
16           contacting said isolated monoclonal antibody or antigen binding fragment thereof  
17 with said tissue sample; and  
18           determining binding of said isolated monoclonal antibody or antigen binding  
19 fragment thereof with said tissue sample;

1           whereby said cancerous cells are isolated by said binding and their presence in said  
2 tissue sample is confirmed.

3

4           Claim 20.     The process of claim 19 wherein the human tumor tissue sample is  
5 obtained from a tumor originating in a tissue selected from the group consisting of colon,  
6 ovarian, lung, and breast tissue.

7

8

9

10

11

12

13

14

15

16

17

18

19